Authorized purpose: AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.
Clinical role
Medical-image display, manipulation, segmentation, quantification, comparison, reporting, or workflow support under professional review.
Images and patients
CT/CTA · Adult lungs, lung lobes, pulmonary parenchyma, and solid or sub-solid lung nodules
Key limitation
Keep in mind: Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Adult lungs, lung lobes, pulmonary parenchyma, and solid or sub-solid lung nodules Input: Supported DICOM images, image metadata, patient data, and user inputs from the labeled imaging devices.
Who uses it?Intended users: Radiologists, physicians, technologists, and other trained medical professionals within the labeled workflow.
What does the software produce?Output: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
What is its most important limitation?Key limitation: Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
Clinical takeaway. Clinical role: AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and regression testing and performance testing of the lesion segmentation algorithm on multiple vendor test data from 273 subjects in the United States and 254 subjects in Germany, with ground truth from two board certified radiologists and third-radiologist adjudication. Average DICE exceeded the predicate's for solid and calcified nodules, sub-solid nodule DICE was superior to the predicate's solid-nodule DICE, and all subgroup criteria were met. No clinical tests were conducted. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.
Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
The exact FDA document reports software verification and regression testing and performance testing of the lesion segmentation algorithm on multiple vendor test data from 273 subjects in the United States and 254 subjects in Germany, with ground truth from two board certified radiologists and third-radiologist adjudication. Average DICE exceeded the predicate's for solid and calcified nodules, sub-solid nodule DICE was superior to the predicate's solid-nodule DICE, and all subgroup criteria were met. No clinical tests were conducted. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and regression testing have been performed successfully to meet their previously determined acceptance criteria as stated in the test plans." … "Performance testing for AI-Rad Companion (Pulmonary) lesion segmentation algorithm was performed on multiple vendor test data from 273 subjects in the United States and 254 subjects in Germany.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and regression testing and performance testing of the lesion segmentation algorithm on multiple vendor test data from 273 subjects in the United States and 254 subjects in Germany, with ground truth from two board certified radiologists and third-radiologist adjudication. Average DICE exceeded the predicate's for solid and calcified nodules, sub-solid nodule DICE was superior to the predicate's solid-nodule DICE, and all subgroup criteria were met. No clinical tests were conducted. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and regression testing have been performed successfully to meet their previously determined acceptance criteria as stated in the test plans." … "Performance testing for AI-Rad Companion (Pulmonary) lesion segmentation algorithm was performed on multiple vendor test data from 273 subjects in the United States and 254 subjects in Germany.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K233753 FDA decision evidence package for AI-Rad Companion (Pulmonary)
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationAdult lungs, lung lobes, pulmonary parenchyma, and solid or sub-solid lung nodules
Scopeexact submission
Tested versionAI-Rad Companion (Pulmonary) configuration described in K233753
IndependenceSponsor or vendor study
K233753
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K233753 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM images, image metadata, patient data, and user inputs from the labeled imaging devices.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes previously acquired CT DICOM input and validation on specified Siemens, GE, and Philips reconstruction types, with an interface to syngo.CT Lung CAD; verify the installed version, scanner protocol, routing, identity, archive, and external interface locally.
Scope: Exact FDA submission. This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes cloud and edge (on-premise) deployments for AI-Rad Companion (Pulmonary), which builds on AI-Rad Companion Engine platform functionality and teamplay digital platform cloud/edge functionality. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "AI-Rad Companion (Pulmonary) builds on platform functionality provided by the AI-Rad Companion Engine and cloud/edge functionality provided by the Siemens Healthineers teamplay digital platform." … "Deployment Cloud and Edge (on-premise) Cloud and Edge (on-premise) Identical". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes cloud and edge (on-premise) deployments for AI-Rad Companion (Pulmonary), which builds on AI-Rad Companion Engine platform functionality and teamplay digital platform cloud/edge functionality. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "AI-Rad Companion (Pulmonary) builds on platform functionality provided by the AI-Rad Companion Engine and cloud/edge functionality provided by the Siemens Healthineers teamplay digital platform." … "Deployment Cloud and Edge (on-premise) Cloud and Edge (on-premise) Identical". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes previously acquired CT DICOM input and validation on specified Siemens, GE, and Philips reconstruction types, with an interface to syngo.CT Lung CAD; verify the installed version, scanner protocol, routing, identity, archive, and external interface locally.
Exact FDA submission
Checked 2026-09-04
This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only radiologists, physicians, technologists, and other trained medical professionals within the labeled workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K233753 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA package describes previously acquired CT DICOM input and validation on specified Siemens, GE, and Philips reconstruction types, with an interface to syngo.CT Lung CAD; verify the installed version, scanner protocol, routing, identity, archive, and external interface locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Monitor K233753 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Only adult DICOM images are valid input; the summary states patients 22 years and older. The software is an adjunct, is not designed to detect findings beyond the prespecified list, and qualified clinicians must review original images.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
20Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.